Bone Biologics filed a prospectus supplement for an at-the-market offering to sell up to 1.06 million shares of common stock through H.C. Wainwright as sales agent. The maximum aggregate market value of shares eligible for sale under the prospectus supplement is USD 1.06 million. Bone Biologics said it previously sold about USD 1.7 million of common stock under the same sales agreement using a prior shelf registration statement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-010080), on March 13, 2026, and is solely responsible for the information contained therein.